Description
The abstract mentions ApoE’s influence in the ATX(N) biomarker framework but doesn’t specify how genetic risk should be weighted against biomarker data. This integration is crucial for implementing genomic-based precision medicine in routine AD care.
Gap type: open_question Source paper: Apolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway. (2024, Nature neuroscience, PMID:38898183)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:43.147283+00:00”, “resolution_summary”: “Resolved by hypothesis h-26353f7f59: Temporal order is subtype-specific rather than universal. Supporting evidence includes debate sess_SDA-2026-04-14-gap-pubmed-20260410-184126-b2c3e2e8.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-26353f7f59”, “title”: “Temporal order is subtype-specific rather than universal”, “score”: 0.23, “reason”: “4 token overlaps; entity overlap: apoe”, “analysis_id”: “SDA-2026-04-25-gapdebate-e849205bca”, “target_gene”: “APOE, SORL1, NTRK1, BIN1, PICALM”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.73, “confidence_score”: 0.76, “status”: “proposed”, “pubmed_evidence_ids”: [“28894304”, “31367008”, “34815562”, “36348357”, “37086935”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-184126-b2c3e2e8”, “title”: “This study shows APOE4 carriers have enhanced beneficial innate immune responses, directly contradicting the established view of APOE4 as purely detrimental in neurodegeneration. This paradox challenges fundamental assumptions about APOE4’s role in AD pathogenesis.\n\nGap type: contradiction\nSource paper: APOE genotype-specific differences in the innate immune response (2021, JAMA Neurology, PMID:33432245)”, “score”: 0.415, “reason”: “6 token overlaps; entity overlap: apoe, pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-184126-b2c3e2e8”, “quality_score”: 0.6, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062222-cc3bcb47”, “title”: “While the abstract mentions identifying subcellular roles of protein interactions, the mechanistic principles governing how interaction networks specify subcellular function remain unclear. This knowledge gap limits our ability to predict how disease mutations disrupt cellular compartmentalization in neurons.\n\nGap type: open_question\nSource paper: A reference map of the human binary protein interactome. (2020, Nature, PMID:32296183)”, “score”: 0.402, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062222-cc3bcb47”, “quality_score”: 0.95, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731”, “title”: “The abstract identifies BACE1 as an attractive drug target but doesn’t address its normal physiological roles. Understanding these functions is critical to predict potential adverse effects of BACE1 inhibitors in therapeutic development.\n\nGap type: open_question\nSource paper: BACE1: the beta-secretase enzyme in Alzheimer’s disease. (2004, Journal of molecular neuroscience : MN, PMID:15126696)”, “score”: 0.401, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1_task_9aae8fc5”, “title”: “The abstract identifies APOE4 association with increased TDP-43 pathology but the mechanistic link is unexplained. This connection could reveal novel therapeutic targets since APOE4 is the strongest genetic risk factor for AD.\n\nGap type: unexplained_observation\nSource paper: TDP-43 Pathology in Alzheimer’s Disease. (2021, Mol Neurodegener, PMID:34930382)”, “score”: 0.396, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1”, “quality_score”: 0.61, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974_20260412-213444”, “title”: “The abstract suggests that Aβ-tau synergy could explain negative results from anti-Aβ trials, contradicting the expectation that targeting the presumed initiating pathology would be therapeutic. This contradiction has major implications for therapeutic strategy design.\n\nGap type: contradiction\nSource paper: Synergy between amyloid-β and tau in Alzheimer’s disease. (2020, Nature neuroscience, PMID:32778792)”, “score”: 0.387, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-12-gap-pubmed-20260410-180503-a7a03974”, “quality_score”: 0.7, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}